A double-blind randomized discontinuation phase-ii study of sorafenib (BAY 43-9006) in previously treated non-small-cell lung cancer patients: Eastern cooperative oncology group study E2501

Heather A. Wakelee, Ju Whei Lee, Nasser H. Hanna, Anne M. Traynor, David P. Carbone, Joan H. Schiller

Research output: Contribution to journalArticle

42 Scopus citations

Fingerprint Dive into the research topics of 'A double-blind randomized discontinuation phase-ii study of sorafenib (BAY 43-9006) in previously treated non-small-cell lung cancer patients: Eastern cooperative oncology group study E2501'. Together they form a unique fingerprint.

Medicine & Life Sciences